A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2012

At a glance

  • Drugs Fipamezole (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms FJORD
  • Most Recent Events

    • 27 Jun 2012 Results published in Neurology.
    • 13 Jul 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 30 Jun 2009 Positive efficacy results reported in a Santhera media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top